sector medic suppli devic
 mix lower tax drive ep upsid
messag turn mix sale come shi
consensu upsid surgic enough off-set modest vision miss
meanwhil although ep beat consensu upsid came lower
expect tax rate stori similar full year guidanc tax lower
interest expens account entir rais midpoint result
view fundament outlook littl chang fulli reflect stock trade
revis ntm ep estim maintain neutral rate
mix miss tax boost ep revenu
pro forma miss consensu adjust ep yoy came
ahead street expect without benefit lower tax rate howev
estim ep would miss consensu penni despit top-lin miss
momentum remain strong across busi csi
post solid growth quarter comp set get tougher howev
see like high water mark compani growth near term
overal manag narrow sale outlook underli
earn growth remain unchang full year revenu expect
come vs previous underli growth still peg
meanwhil adjust ep project cc
previous howev increas midpoint made entir
benefit lower tax benefit lower interest expens off-set
partial increment headwind fx result guidanc underli
ep growth remain unchang
turn back quarter coopervis sale pro forma came
consensu growth mark continu trend
quarter perform come yoy comp easier
categori perspect shortfal broad base toric cc single-
use sphere cc multifoc cc came
street respect partial off-set upsid
single-us sphere categori cc includ
emerg specialti len portfolio myopia geograph basi intern
busi deceler sequenti strength asia pacif cc
off-set slowdown emea cc meanwhil america growth
cc sequenti estim silicon hydrogel len sale rose
driven continu momentum daili sih franchis cc
meanwhil perform extend wear sih brand held steadi sequenti
biofin avaira combin grow cc manag lower revenu
guidanc howev underli growth peg
vs previous model call coopervis
revenu come pro forma
meanwhil coopersurg revenu pro forma top consensu
paragard anoth strong quarter sale came
forecast manag stick mid- high-singl
digit growth outlook paragard go forward franchis continu strength
aggress invest promot distribut lead us believ outlook
could prove conserv elsewher base offic surgic product busi
pro forma turn solid perform fertil segment pro forma
deceler sequenti difficult comp fiscal manag slightli
rais csi guidanc call sale underli vs
model coopersurg revenu
pro forma continu page
page analyst certif import disclosur
turn back contact estim global len sale rose cc calendar
essenti line gain first half
overal four major manufactur combin sale
report basi ex-fx repres deceler constant
currenc gain bausch lost share
sequenti alcon gain ground vs stori revers
yoy basi howev alcon cede share compar
 bausch make increment headway
believ data show contact len market remain healthi overal cooper
continu outperform backdrop compani trail
underli growth rate stand vs competitor see figur
see world-wide contact len growth moder
reacceler back new product launch share
perspect believ remain well posit benefit daili len adopt
increas silicon hydrogel penetr model call compani
remain net share taker increas daili sih competit dynam
keep eye move forward howev bausch alcon pois roll
new product segment next month extent alcon
drive acceler contact len growth particular interest
biggest laggard space past year see figur
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
top line lower expect tax rate drove ep beat cooper fiscal
gross margin yoy consensu
off-set tight expens manag howev sg spend rose
yoy sale came street expect meanwhil
spend grew yoy sale lower consensu collect
result fiscal ebita margin yoy street
estim bottom line adjust ep came higher
consensu due lower expect tax rate vs consensu without
benefit estim ep would come penni shi street
page analyst certif import disclosur
continu demonstr solid underli momentum
core busi see outlook fulli reflect stock current level
model call compani post ep total
revenu pro forma compar previou estim
respect meanwhil earn estim move
share trade revis ntm ep
estim premium large-cap med-tech averag solid top
line growth rate vs large-cap group would seem argu premium
valuat compani earn growth appear like lag group averag
least next two year also view cooper outsiz exposur
currenc swing rise interest rate consum categori believ could
prove highli cyclic next econom downturn argument multipl
expans result maintain neutral rate
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal ad scale increment growth
coopersurg women health franchis often overlook investor
expect csi account overal revenu
growth fuel primarili compani invest
half dozen deal build lead posit ivf genet test
market follow acquisit paragard intrauterin devic
believ long-term fundament market appeal see
grow scale csi neg broader invest case complic
stori believ investor would prefer look sole contact len play
share current trade ntm ep ntm ebitda
repres premium large-cap med-tech group averag price-to-earnings
large-cap group would seem argu slight premium valuat dont
see compani sustain bottom line growth trajectori meaning differenti
group averag also view cooper outsiz exposur
currenc swing rise interest rate consum categori believ could
prove highli cyclic next econom downturn argument multipl
expans result maintain neutral rate
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur strong dollar rise interest rate
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
